Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double‐blind, placebo‐controlled trial
These results demonstrated that empagliflozin partially suppressed the hypoxia-induced angiogenic factors overproduction in addition to a declining trend in ACR in the early stage of diabetic kidney disease, which might contribute to the mechanisms of reno-protective effects of this agent (jRCTs051200147).
Authors
- Yoko Omura‐Ohata (ORCID: https://orcid.org/0009-0008-0617-7444)
- Shu Kasama
- Mayu Tochiya (ORCID: https://orcid.org/0000-0001-5571-7015)
- Tamiko Tamanaha (ORCID: https://orcid.org/0009-0006-9440-1930)
- Naoki Ozu (ORCID: https://orcid.org/0009-0004-8790-587X)
- Ryuzo Takashima
- Takeshi Aiba
- Kiminori Hosoda
- Michio Noguchi
- Masato Kasahara
- Qingxing Chen
- Hisashi Makino
- Kazuhiko Tsuruya
- Hyohun Park
- Fumiki Yoshihara
Institutions
- National Cerebral and Cardiovascular Center (JP)
- Suita Municipal Hospital (JP)
- Takatsuki General Hospital (JP)
- Nara Medical University (JP)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-01-26
- DOI
- https://doi.org/10.1111/dom.70485
- Primary Topic
- Lipid metabolism and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00